Discovered by Osi’s diabetes and obesity research team, PSN821 demonstrated both effective glucose lowering and substantial reductions of body weight in pre-clinical studies. PSN821 is said to be the third development candidate discovered in-house that the company has moved into clinical development in 2008.
The double-blind, placebo-controlled, ascending single oral dose study is designed to provide preliminary information on the safety, tolerability and pharmacokinetics of PSN821 in healthy lean and overweight or obese subjects and patients with type 2 diabetes, as well as provide preliminary information on the effects of PSN821 on acute glucose control in the patient group.
Anker Lundemose, president of (OSI) Prosidion, said: “We are encouraged by the dual profile which has been observed for PSN821 and believe that it has the potential to be the first orally available therapy for type 2 diabetes that delivers both glucose control and substantial weight loss.
“PSN821 and our anti-obesity agent, PSN602, are part of an innovative strategy to discover and develop differentiated molecular targeted therapies for the treatment of type 2 diabetes and obesity.”